MedWarn.org
  • Alerts
  • Drugs
    • ADHD Medications
    • Allergy Treatments
    • Antidepressants
    • Antipsychotics
    • Antibiotics
    • Antiseizure
    • Arthritis
    • Cancer Treatments
    • Cardiovascular
    • Diabetes Treatments
    • Dietary Supplements/Weight Loss
    • Erectile Dysfunction
    • Gastrointestinal
    • Hormone Therapy
    • Oral Contraception
    • Pain Relief
    • Respiratory
    • Skin Conditions
    • Sleep
  • Vaccines/Biologics
    • Blood Products
    • Genetic Testing
    • Tissues
    • Vaccines
  • Devices
    • 3D Printed
    • Autoinjectors
    • Brain Devices
    • Breast Implants
    • Cardiac Devices
    • Contraceptive Devices
    • Cyber Security
    • Home Health Devices
    • Hip Implants
    • Infusion Pumps
    • Respiratory Systems
    • Stents
    • Surgical Devices
    • Transvaginal Mesh
  • Tobacco
  • Resources
    • Product Safety and the FDA
    • Product Recalls
    • Product Liability Lawsuits
    • Questions For A Lawyer
    • Get Help
  • About Us

Alerts, Recalls, and Legal Headlines

Sign-up to receive recall notices, medical news, and litigation updates.

SIGN-UP

Research Alert: Primary ADT Doesn't Increase Survival Rate for Men With Prostate Cancer

3/23/2014

0 Comments

 
Primary androgen-deprivation therapy (ADT) is widely used to treat localized prostate cancer in patients who have opted not to have surgery or radiation therapy.  However, a study published last week in the American Society of Clinical Oncology found that primary ADT did not provide any prostate cancer survival benefit to patients.  Although the study showed a small clinical benefit for a subgroup of high-risk cases, researchers concluded that primary ADT is not an effective therapy for most men.
[1] Potosky, A., "Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer," American Society of Clinical Oncology, doi:10.1200/JCO.2013.52.5782 (March 17, 2014).
[2] Bankhead, C., "ADT: No Help as Primary Tx for Prostate Cancer,"  medpage TODAY (March 17, 2014). 
0 Comments

FDA approves AVEED, Endo's Testosterone Drug for Men

3/8/2014

0 Comments

 
Picture
After rejecting it three times, FDA has now approved AVEED, a new testosterone and castor oil therapy manufactured by Endo International to treat male hypogonadism.  Male hypogonadism is characterized by low production of testosterone which is responsible for maintaining muscle bulk, bone growth and sexual function.   The FDA had been concerned about the risk of the castor oil causing blockages in blood vessels in the lungs and complications linked to post-injection reactions.  However, FDA determined that the benefits of testosterone therapy outweighed these risks.  Following the approval, AVEED is expected to be available later in March.
[1] Reuters, "FDA approves Endo International's testosterone drug" (March 6, 2014).
[2] FDA Approved Drug Products, AVEED (March 5, 2014).


0 Comments

FDA Says Facebook Page for Tirosint Violates FD&C Act

2/28/2014

0 Comments

 
For the first time, FDA has issued a letter notifying a company that representations made on a drug's Facebook page violate the Federal Food, Drug & Cosmetic Act.  The company, Institut Bochimique SA (IBSA), was cited by FDA for maintaining a Facebook page for the drug Tirosint (levothyroxine sodium) that is false or misleading in that it makes representations about the efficacy of Tirosint, but fails to communicate any information about the drugs risks as required by FDA regulations.

Tirosint is approved as a replacement or supplemental therapy for hypothyroidism.  While the Facebook page makes suggestions regarding the use of Tirosint for patients with hypothyroidism, it fails to convey that Tirosin is not indicated for transient hypothyroidism during the recovery phase of subacute thyroiditis.   

FDA requests that IBSA immediately discontinue the use of the misleading material on the Facebook page and respond to the FDA in writing on or before March 10, 2014.

[1] FDA NDA #021924 TIROSINT (levothyroxine sodium) capsules, for oral use MA #42, Reference ID: 3461139 (2/24/2014).
[2] www.facebook.com

 
0 Comments

    Archives

    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    September 2013
    July 2013
    June 2013
    May 2013
    March 2013
    January 2013
    July 2012
    June 2012
    March 2012
    February 2012
    August 2011
    December 2010
    August 2010
    February 2009
    July 2008

    RSS Feed

    Categories

    All
    3D Printing
    3D Printing
    Acid Reducers
    Acne Treatments
    ADHD
    Allergies
    Antibiotics
    Antidepressants
    Anti-Epilepsy
    Antipsychotics
    Antiviral
    Arthritis
    Aspirin
    Asthma
    Autism
    Birth Control
    Birth Defects
    Blood Products
    Bone
    Brain
    Cancer
    COPD
    Cyber Crime
    Diabetes
    Dietary Supplements
    Dna-testing
    E-cigarettes
    Electronic Health Records
    Eliquis
    Epilepsy
    FDA/Approvals
    FDA Recalls
    FDA/Recalls
    FDA Warnings
    FDA Warnings
    Hearing-devices
    Hearing Loss
    Heart
    Hemophilia
    Hip Implants
    Hormone
    HPV
    Infants
    Infusion Pump
    Invokana
    Legal News
    Migraines
    Mirena
    Monitors
    Multiple Sclerosis
    Pain Relief
    Research
    Resuscitation
    Risperdal
    Sleep
    Stents
    Stroke
    Surgical Device
    Surgical Device
    Topamax
    Transvaginal Mesh
    Vaccine
    Weight Control
    Weight Control

    RSS Feed



    120x600
Powered by Create your own unique website with customizable templates.
Photos used under Creative Commons from Official U.S. Navy Imagery, madaise, outcast104, archibald jude, Vee-vee